These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Role of AVP in maintenance of circulatory homeostasis during hemorrhagic shock. Hock CE, Su JY, Lefer AM. Am J Physiol; 1984 Feb; 246(2 Pt 2):H174-9. PubMed ID: 6696129 [Abstract] [Full Text] [Related]
5. Beneficial action of a new opiate antagonist (Win 44,441-3) in hemorrhagic shock. Curtis MT, Lefer AM. Eur J Pharmacol; 1982 Mar 12; 78(3):307-13. PubMed ID: 6279411 [Abstract] [Full Text] [Related]
6. Salutary effects of nitrendipine, a new calcium entry blocker, in hemorrhagic shock. Hock CE, Su JY, Lefer AM. Eur J Pharmacol; 1984 Jan 13; 97(1-2):37-46. PubMed ID: 6698110 [Abstract] [Full Text] [Related]
8. Beneficial effect of anisodamine in hemorrhagic shock. Su J, Hock CE, Lefer AM. Naunyn Schmiedebergs Arch Pharmacol; 1984 Apr 13; 325(4):360-5. PubMed ID: 6728045 [Abstract] [Full Text] [Related]
9. Effect of angiotensin II receptor blockade by [Sar1-Ala8]angiotensin II in hemorrhagic shock. Trachte GJ, Lefer AM. Am J Physiol; 1979 Feb 13; 236(2):H280-5. PubMed ID: 311160 [Abstract] [Full Text] [Related]
10. Beneficial effect of arachidonic acid during hemorrhagic shock in the dog. Flynn JT, Lefer AM. Circ Res; 1977 Apr 13; 40(4):422-8. PubMed ID: 844155 [Abstract] [Full Text] [Related]
11. Salutary consequences of blockade of platelet activating factor in hemorrhagic shock. Stahl GL, Bitterman H, Terashita Z, Lefer AM. Eur J Pharmacol; 1988 May 10; 149(3):233-40. PubMed ID: 3409951 [Abstract] [Full Text] [Related]
12. Beneficial actions of antagonism of peptide leukotrienes in hemorrhagic shock. Bitterman H, Smith BA, Lefer AM. Circ Shock; 1988 Mar 10; 24(3):159-68. PubMed ID: 3383353 [Abstract] [Full Text] [Related]
13. Anti-shock actions of a new converting enzyme inhibitor, enalaprilic acid, in hemorrhagic shock in cats. Freeman JG, Hock CE, Edmonds JS, Lefer AM. J Pharmacol Exp Ther; 1984 Dec 10; 231(3):610-5. PubMed ID: 6094795 [Abstract] [Full Text] [Related]
14. Protective actions of naloxone in hemorrhagic shock. Curtis MT, Lefer AM. Am J Physiol; 1980 Sep 10; 239(3):H416-21. PubMed ID: 7435587 [Abstract] [Full Text] [Related]
15. Salutary effects of CG-4203, a novel, stable prostacyclin analog, in hemorrhagic shock. Bitterman H, Smith BA, Lefer DJ, Lefer AM. J Cardiovasc Pharmacol; 1988 Sep 10; 12(3):293-9. PubMed ID: 2464101 [Abstract] [Full Text] [Related]
16. Preservation of cellular integrity as a protective mechanism of dexamethasone in hemorrhagic shock in the cat. Trachte GJ, Lefer AM. Arch Int Pharmacodyn Ther; 1978 Apr 10; 232(2):309-20. PubMed ID: 677964 [Abstract] [Full Text] [Related]
17. Beneficial effects of combined thromboxane and leukotriene receptor antagonism in hemorrhagic shock. Patel JP, Beck LD, Briglia FA, Hock CE. Crit Care Med; 1995 Feb 10; 23(2):231-7. PubMed ID: 7867347 [Abstract] [Full Text] [Related]
18. Potentiation of the protective effects of a converting enzyme inhibitor and a thromboxane synthetase inhibitor in hemorrhagic shock. Bitterman H, Phillips GR, Dragon G, Lefer AM. J Pharmacol Exp Ther; 1987 Jul 10; 242(1):8-14. PubMed ID: 3039116 [Abstract] [Full Text] [Related]
19. Novel mechanism of action of a prostacyclin enhancing agent in haemorrhagic shock. Bitterman H, Lefer DJ, Lefer AM. Naunyn Schmiedebergs Arch Pharmacol; 1988 Jun 10; 337(6):679-86. PubMed ID: 3063971 [Abstract] [Full Text] [Related]
20. Beneficial actions of RO 15-1788, a benzodiazepine receptor antagonist, in hemorrhagic shock. Bitterman H, Lefer DJ, Lefer AM. Methods Find Exp Clin Pharmacol; 1987 Jun 10; 9(6):341-7. PubMed ID: 3116357 [Abstract] [Full Text] [Related] Page: [Next] [New Search]